Clinical trialObservationalUnknown
Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues
- Outcome
- Outcome unknown
- Phase
- Observational
- Status
- Unknown
- Study type
- Observational
- Start
- 1 May 2018
- Listed end
- 1 June 2021
- Enrollment
- 50 participants
- Sites
- 1
- Primary outcomes
- Number of organoids successfully generated from pancreatic cancer biopsies
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 7 January 2020
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
We are going to establish "organoid" models from pancreatic cancer biopsies achieved via EUS-FNA. Then the sensitivity of the selected FDA-approved anti-cancer drugs will be tested in these organoids.
Detailed description public domain (ClinicalTrials.gov)
The survival rate of pancreatic cancer, a kind of malignant tumor, remains poor due to lack of effective treatments. Recently, a new model called "organoid" has been generated from human and murine pancreatic cancer tissues. These organoids are developed from large pieces of surgical tissues or small biopsies taken from EUS-FNA guided samples. Here in our study we are going to establish "organoid" models from pancreatic cancer biopsies achieved via EUS-FNA. After successful generation of these organoids, we will treat them with the selected FDA-approved anti-cancer drugs, and assess the responses to these anti-cancer agents in our established organoids.
Intervention public domain (ClinicalTrials.gov)
Procedure: Biopsy. Two extra EUS-FNA guided pancreatic biopsies collected for only research purposes.
Primary outcome public domain (ClinicalTrials.gov)
Number of organoids successfully generated from pancreatic cancer biopsies. Successful isolation of pancreatic cancer organoids within 2 weeks of EUS-FNA operation will be defined as successful establishment of an organoid. We will calculate the total number of organoids generated in our center. Time frame: 09/01/2018-06/01/2019.
Secondary outcome public domain (ClinicalTrials.gov)
Response of the pancreatic cancer organoids to the selected anti-cancer drugs. Time frame: 06/01/2019-06/01/2020.
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria: * 1\) Patients suspected to have pancreatic cancer who will receive EUS-FNA for diagnosis; 2) Patients who have signed the informed consent. Exclusion Criteria: * 1\) Those who are under the age of 18; 2) Patients who have received adjuvant chemoradiotherapies or other anti-tumor therapies; 3) Patients with critical illness and cannot tolerate the operations; 4) Women who have been pregnant or are planning to be pregnant.
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 50 participants (estimated).